Loading patent…
AssigneeEirgen Pharma Ltd.
InventorsCharles W. Bishop, Stephen A. Strugnell, Akhtar Ashfaq, Reem Elamein Elsiddig, Colm Nulty
Estimating the term…
Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.
A method of treating a SARS-CoV-2 infection, comprising administering to a subject in need thereof an effective amount of a sustained release formulation of a 25-hydroxyvitamin D compound to treat a SARS-CoV-2 infection,
-13. (canceled)
-19. (canceled)
(canceled)
(canceled)
-31. (canceled)
-41. (canceled)
-103. (canceled)
-159. (canceled)
A dosing regimen for treating a patient having or suspected of having a SARS-CoV-2 infection, comprising administering to the patient an extended release dosage form comprising a controlled release excipient and a pharmaceutically effective amount of 25-hydroxyvitamin D3 and wherein the dosage form is administered in a maintenance dosing period in an amount of 30 to 70 μg/day and preceded by a loading dosing period in an amount in a range of 300 to 900 μg/day on days one, two or three of treatment, wherein the patient's vitamin D metabolite ratio (VMR, calculated as 100 times the ratio of serum 24,25-dihydroxoxyvitamin D3 to serum 25-hydroxyvitamin D3) remains substantially constant or decreases during the maintenance dosing period.
Dependencies are inferred from the claim text.